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Abstract
Background: The six-dose regimen of artemether-lumefantrine (AL) is now considered the gold
standard for the treatment of uncomplicated Plasmodium falciparum malaria. There are few reports
evaluating co-artemether in very young Nigerian infants and children. Results of the evaluation of
the six-dose regimen in very young infants and children in Nigeria are presented in this report.
Methods: As part of a larger African study, this open label, non-comparative trial, assessed the
efficacy and safety of six-dose regimen of AL tablets in 103 Nigerian infants and children weighing
between five and 25 kg suffering from acute uncomplicated malaria. Treatment was administered
under supervision over three days with children as in-patients. 12-lead ECG tracings were taken
pre-treatment and at day 3.
Results: Ninety-three infants and children completed the study as stipulated by the protocol. Mean
fever and parasite clearance times for the intent to treat population (ITT) were 24.9 h ± (1.28) and
26 h ± (4.14) and the corresponding figures for the per-protocol population (PP) were 19.24 h ±
13.9 and 25.62 h ± 11.25 respectively. Day 14 cure rates for the ITT and PP were 95.1% and 100%
respectively while day 28 cure rates were 91.3% and 95.7% respectively. The overall PCR corrected
day 28 cure rate was 95.1% for the ITT. The six-dose regimen of AL was well tolerated with no
drug-related serious adverse events. Although six patients recorded a QTc prolongation of > 60
ms on D3 over D0 recording, no patient recorded a QTc interval > 500 ms.
Conclusion: The six-dose regimen of AL tablets is safe and effective for the treatment of acute
uncomplicated malaria in Nigerian infants and children weighing between five and 25 kg.
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Background
The deleterious consequences of malaria continue to
increase in endemic areas as a result of the emergence and
widespread dissemination of drug resistant Plasmodium
falciparum [1,2]. Children below five years of age are most
at risk in endemic countries. Safe and effective drugs with
long effective clinical lives for malaria therapy are urgently
needed in Africa. Artemether-lumefantrine (AL) is a fixed-
dose combination tablet containing 20 mg of artemether
and 120 mg of lumefantrine. This combination combines
the benefits of a rapid schizonticidal effect of artemether
with a slow but longer acting schizonticidal effect of lume-
fantrine. AL was first made available as a four-dose regi-
men, which was found to be safe and efficacious in areas
where drug resistance in P. falciparum was rare at the time,
such as China and India [3,4], but not in Thailand, an area
where multi-drug resistance is common [5]. Subsequent
trials of the six-dose regimen in Thailand found it to be
well tolerated with high cure rates similar to those with
high dose mefloquine plus artesunate – the standard of
care for acute uncomplicated malaria in Thailand [6,7].
The six-dose regimen is now the global standard regimen
for AL [8].
The safety and efficacy of the six-dose regimen of AL in
infants and children weighing between five and 25 kg for
the treatment of acute uncomplicated falciparum malaria
was evaluated in this study. Special attention was paid to
the response to treatment by non-immune infants
between five and 10 kg. Infants weighing between five and
10 kg, who had never had an episode of malaria prior to
the current episode were considered to be non-immune to
malaria. Evaluations for neurotoxicity were included in
this study based on reports of neurotoxicity associated
with artemisinins [9,10]. In addition, electrocardio-
graphic recordings were performed on days 0 and 3, due
to the structural similarity between lumefantrine and
halofantrine, although previous studies had unequivo-
cally demonstrated that lumefantrine lacks the cardiotox-
icity of halofantrine [7]. Cardiotoxicity (QTc interval
prolongation and arrhythmias) associated with the use of
the latter compound has been reported [11].
This report is based on data from the "Nigerian Coartem®
Treatment Group" of the multicentre study evaluating the
efficacy and safety of AL in the management of malaria in
African infants and children [12].
Patients and methods
The study was conducted at the General Out Patient Clinic
and paediatric wards of the University College Hospital,
Ibadan, south-western Nigeria between August 2002 and
February 2003. Malaria transmission is intense through-
out the year in the study area with peak transmission
occurring during the rainy season months of May to Octo-
ber. Ethical approval for the study was obtained from the
Joint University of Ibadan/University College Hospital
Institutional Review Committee and the ethical review
board of the World Health Organization, Geneva, before
commencement. The study was conducted according to
the declaration of Helsinki and its amendments. Good
clinical practice was also adhered to and a written
informed consent or witnessed verbal informed consent
was obtained from the parent or guardian of each enrolled
child before any study related procedure was performed.
Study design
In an open label, non-comparative study design, children
weighing between five and 25 kg suffering from con-
firmed acute uncomplicated falciparum malaria were
treated with AL (Coartem®). An open label study design
was chosen because at the time there were no affordable
products approved by regulatory authorities for the treat-
ment of malaria in children weighing < 10 kg; thus no
suitable comparator was available. The study population
was stratified into three body weight groups as follows: 5-
<10 kg, 10-<15 kg and 15-≤25 kg as body weight groups
(BWG) 1, 2 and 3 respectively. Children weighing 5-<10
kg (BWG1) constituted half of the study population in the
design so as to have enough data for evaluation in this
group of children.
Inclusion criteria for the study were body weight 5 kg to <
25 kg, microscopically confirmed symptomatic acute
uncomplicated falciparum malaria, asexual parasite den-
sity between 1,000 and 100,000/μL, axillary temperature
≥ 37.5°C and informed consent by the parent or guardian.
Patients who had clinical features of severe malaria, other
plasmodial infection, severe malnutrition, history of hav-
ing received halofantrine or any other drug known to
influence cardiac function within four weeks prior to the
screening visit were excluded from the study. Other exclu-
sion criteria were severe gastrointestinal disease or hyper-
sensitivity to the study drugs. Patients were withdrawn
from the study if a serious adverse event, abnormal labo-
ratory values or test procedures, unsatisfactory therapeutic
effect or protocol violation occurred. Reasons for discon-
tinuation from the study were withdrawal of consent,
vomiting of replacement dose of study drug, loss to fol-
low-up or death.
Clinical and laboratory evaluation
Patients fulfilling eligibility criteria were allocated to the
appropriate body weight group. A complete medical his-
tory, physical examination including vital signs, specific
neurological examination and baseline signs and symp-
toms of malaria for specific safety evaluation of treatment
emergent signs and symptoms (TESS) was carried out. All
worsening, and newly occurring signs and symptoms of
malaria after baseline, whether considered drug-related orMalaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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not, but before recurrence of parasitaemia were defined as
TESS. Thick and thin blood films were prepared from a
finger prick and stained with 10% freshly prepared
Giemsa stain and examined using x1,000 magnification
of a light microscope for parasite detection, quantification
and morphology. Parasite density was calculated using
individual patient's white blood cell count. Blood (3.5
ml) was collected for haematology and clinical chemistry
evaluation on days 0, 3 and 28. Haematology evaluation
included haematocrit, haemoglobin, red blood cell count,
white blood cell count with differential, platelet count
and glucose-6-phosphate dehydrogenase activity, while
blood chemistry evaluation included blood glucose,
serum bilirubin, creatinine, alanine transaminase (ALT),
aspartate transaminase (AST) and γ-glutamyl transferase.
Urine measurements were performed when considered
necessary and parameters evaluated included specific
gravity, haemoglobinuria, proteinuria and sediment.
Blood spots were blotted on isocode stix for polymerase
chain reaction (PCR) before commencement of drug ther-
apy and at recurrence of parasitaemia for genotyping of
isolates to distinguish between recrudescence and re-
infection [13]. In addition, 12-lead electrocardiographic
tracings were recorded before treatment and at day 3. Hae-
matology, blood chemistry and urine examinations were
repeated at days 3 and 28. Therapeutic response was
assessed by clinical and parasitological parameters.
Drug therapy and follow-up
The study consisted of two phases: a treatment phase and
a post treatment phase. During the first four days, termed
the treatment phase, patients were admitted to the ward
for drug therapy. Enrolled patients received Coartem®
(Novartis Pharma AG; Basel) which consists of artemether
(20 mg) and lumefantrine (120 mg) per tablet supervised
by a doctor or nurse. Children weighing 5 to < 15 kg
received 6 doses of 1 tablet each of AL at 0, 8, 24, 36, 48
and 60 hours while children weighing 15 to < 25 kg
received 2 tablets of study drug at similar time points as
above. Study drug was administered with sweetened con-
densed milk for older children and feeding encouraged
soon after dosing while younger children took the study
drug with water and were breast-fed immediately follow-
ing drug administration. Patients were subsequently seen
as outpatients daily for four days (up to day 7) and then
on days 14, 21 and 28 during the post treatment phase.
Efficacy assessment
Efficacy evaluation was based on parasitological cure rates
at days 7, 14 and 28. Cure rates at days 7, 14 and 28 were
defined as the proportion of patients cleared of asexual
parasitaemia within the specific time intervals of initia-
tion of treatment with AL without recrudescence within
the specified days. Re-infection was distinguished from
true recrudescence by genotyping using PCR [13]. In addi-
tion to cure rates, mean fever clearance time (FCT) and
mean parasite clearance time (PCT) were determined. PCT
was defined as the time elapsing from drug administra-
tion until the clearance of parasitaemia. FCT was defined
as the time from drug administration until axillary tem-
perature fell below 37.5°C and remained so for at least 48
hours. All patients with recurrence of parasitaemia
received oral amodiaquine (25 mg/kg body weight) over
3 days plus oral sulphadoxine-pyrimethamine (25 mg/kg
of sulphadoxine component to the nearest next quarter
tablet) as a single dose co-administered on the day of
starting re-treatment.
Safety evaluation
Safety evaluation was based on the intent to treat popula-
tion (ITT). Safety assessment consisted of monitoring and
recording of all adverse events whether volunteered, dis-
covered by questioning or detected by examination in
addition to clinically significant changes in haematology,
blood chemistry and urine values. Adverse events infor-
mation was collected by evaluating TESS. An adverse
event was regarded as any undesirable sign, symptom or
medical condition occurring after starting the study drug,
whether the event was considered to be related to study
drug or not. Any signs and symptoms that appeared newly
or worsened from baseline were recorded as adverse
events. Standard 12-lead electrocardiographic tracings
were done pre-treatment on day 0 and at day 3 as part of
safety evaluation. Primary data as well as changes from
baseline were derived from an independent blinded
review of electrocardiographic results. Corrected QTc
interval values were calculated according to Bazett's for-
mula (QTc = QT/vRR) and Fridericia's formula (QTc/
3vRRms). Values < 430 and 450 ms were classified as nor-
mal for males and females respectively, 431–450 and
451–470 ms, borderline while > 450 and > 470 ms were
classified as prolonged.
Statistical methods
Safety variables were summarized descriptively by body
weight group and overall. ITT and safety populations were
defined as all patients who received at least one dose of
study medication. Adverse events, including signs and
symptoms of malaria that had increased in intensity as
compared to baseline, were summarized by MedDRA pri-
mary system organ class, preferred term, intensity, and
relationship to study drug. Laboratory data, including
changes from baseline, were summarized with descriptive
measures by time point and classifications according to
the reference ranges were summarized in shift tables. ECG
data were summarized accordingly. All efficacy analysis
was based on the ITT with supportive analyses on the per-
protocol population (PP). The PP population was made
up of ITT patients who received all six doses of medication
and who adhered to the study protocol. The variablesMalaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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were summarized using descriptive statistics (mean,
standard deviation, median, minimum and maximum or
frequency and percentage, as appropriate) by body weight
group and overall. PCT and FCT were derived by means of
the Kaplan-Meier method. 95% confidence intervals for
the cure rates were determined using the exact Pearson-
Clopper limits. Time to fever clearance and time to para-
site clearance were evaluated using Cox's proportional
hazards regression analysis.
Results
Patient demographics at presentation
One hundred and three consecutive children screened
between August 2002 and February 2003 at the study cen-
tre and who fulfilled the inclusion criteria were enrolled
in the study. The distribution of the ITT population con-
sisted of 50 in BWG 1, 37 in BWG 2 and 16 in BWG 3
(Table 1). The youngest child in this study was five weeks
old. The age distribution of children enrolled in the study
is shown in Table 2. There were 50 males and 53 females
in the ITT population. Safety evaluation was based on the
ITT population which is also the safety population.
Ninety-three of 103 (90.3%) enrolled patients completed
the study as stipulated by the protocol. The PP population
consisted of 45 in BWG1, 34 in BWG2 and 14 in BWG3.
Gender disposition of PP was similar to that of ITT. Rea-
sons for exclusion of 10 patients from the PP included loss
to follow up (2), withdrawal of consent (1) protocol vio-
lation (6) and death (1). One patient in BWG2 died on
the ninth day of study from severe gastroenteritis, which
was not considered drug-related. Criteria for withdrawal
for protocol violation in the study included unauthorized
use of anti-malarial medication during follow up and
more than one parasite count missing. All patients
excluded from the PP population except those who were
lost to follow up and the child who died were followed up
to 28 days for safety evaluation.
Efficacy assessment
P. falciparum was the only species identified in the blood
films of enrolled patients. Baseline parasite density was
similar in all body weight groups (Table 1). A total of
75.3% and 89.9% of patients were free of patent parasitae-
mia at 24 and 60 hours, respectively, while all patients
were free of patent parasitaemia by day 3 evaluation. Cure
rates in PP at day 7 and day 14 were 100% for all body
weight groups while the cure rates in the ITT at the same
time points were 98.1% and 95.1%. Day 28 cure rates in
the PP population without PCR correction were 95.6%,
94.1% and 100% among children in BWG1, 2 and 3
respectively while day 28 cure rates for BWG1, 2 and 3
among the ITT populations were 92%, 89.2% and 93.8%.
These gave overall uncorrected cure rates of 95.7% and
91.3% for the PP and ITT populations on day 28 respec-
tively. Four patients had patent parasitaemia at day 28; all
four were shown to be new infections by PCR. Details of
response of infection to therapy are shown in Table 3. In
addition, fever clearance in response to AL was rapid.
95.6%, 97.1%, 100% of children in BWG1, 2 and 3
respectively, recorded axillary temperatures below 37.5°C
by 36 hours after starting drug treatment.
Safety assessment
The study drug was well tolerated and no patient was
withdrawn due to recurrent vomiting or poor tolerability.
Anaemia (n = 59) was the most frequently reported
Table 1: Clinical features at baseline of children suffering from acute uncomplicated malaria by body weight group (ITT population)
Characteristic BWG1 BWG2 BWG3 TOTAL
Number enrolled and treated (ITT) 50 37 16 103
Sex (M: F) 21:29 21:16 8:8 50:53
Age (years)
Mean ± SD 1.3 ± 0.56 3.4 ± 1.3 6.5 ± 1.76 2.8 ± 2.13
Range 0.2 – 3.1 0.9 – 6.8 4.0 – 9.9 0.2 – 9.9
Non-Immune (n) 15 - - 15
Weight (kg)
Mean ± SD 8.0 ± 1.05 12.3 ± 1.52 18.7 ± 1.87 11.2 ± 4.0
Range 5.1 – 9.6 10 – 14.5 15.5 – 22 5.1 – 22
Parasite density (/μL)
Mean ± SD 21,286 ± 19,900 32,668 ± 27,400 27,656 ± 26,074 26,364 ± 24,135
Range 2,927–95,546 2,112–106,425 2,332–104,919 2,112–106,426
Temperature (°C)
Mean ± SD 38.9 ± 0.80 38.8 ± 0.86 39.0 ± 0.64 38.9 ± 0.80
Range 37.6 – 40.8 37.6 – 40.3 37.9 – 39.8 37.6 – 40.8
Haemoglobin (g/L)
Mean ± SD 90.2 ± 14.73 92.7 ± 16.41 103.4 ± 15.87 93.3 ± 16.04
Haematocrit (%)
Mean ± SD 27.9 ± 4.12 28.6 ± 4.17 30.9 ± 4.77 28.6 ± 4.33Malaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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adverse event by laboratory evaluation, while cough (n =
33) was the most often volunteered adverse event
reported. Respiratory infection (n = 31), diarrhoea (n =
20), vomiting (n = 18), rash (n = 17), clonus (n = 13) and
insomnia (n = 11) were the next six most common treat-
ment emergent adverse events recorded after baseline but
before recurrence of parasitaemia among study partici-
pants. Other adverse events recorded among patients
included hypothermia (n = 6), hyperreflexia (n = 6) and
distended abdomen (n = 1). Five of the six episodes of
hypothermia occurred among children in BWG1. Mean
haemoglobin level decreased from 93.3 ± 16.04 g/L on
day 0 to 83.2 ± 13.43 g/L on day 3 and increased to 103.2
± 14.76 g/L on day 28 while the number of children with
low neutrophil count on day 0 decreased from 87 to 40 at
day 28. In addition there was no record of eosinophilia,
intravascular haemolysis or leucopaenia (total white
blood cell count < 2,500/mm3) during the study. Bio-
chemical parameters were not adversely affected by the
study drug.
Table 2: Age distribution of patients at baseline by body weight group
Age group (Months) n (%)
BWG1
5-<10 kg
N = 50
BWG2
10-<15 kg
N = 37
BWG3
15-<25 kg
N = 16
Total
5-<25 kg
N = 103
0- = 6 3 (6) ---- ---- 3 (2.9)
> 6 – 12 17 (34) 1 (2.7) ---- 18 (17.5)
> 12 – 24 26 (52) 3 (8.1) ----- 29 (28.2)
> 24 – 48 4 (8) 24 (64.9) 1 (6.3) 29 (28.2)
> 48 – 72 --- 8 (21.6) 7 (43.8) 15 (14.6)
> 72 --- 1 (2.7) 8 (50) 9 (8.7)
TOTAL 50 (100) 37 (100) 16 (100) 103 (100)
Table 3: Clinical and parasitological responses to treatment with artemether-lumefantrine by body weight group
Body weight group
Characteristic BWG1
5-<10 kg
BWG2
10-<15 kg
BWG3
15-<25 kg
Total
5-<25 kg
Cure rates ITT %(n/M)1 (uncorrected) N = 50 N = 37 N = 16 N = 103
Day 7 98.0% (49/50) 97.3% (36/37) 100.0% (16/16) 98.1% (101/103)
Day 14 96.0% (48/50) 94.6% (35/37) 93.8% (15/16) 95.1% (98/103)
Day 28 92.0% (46/50) 89.2% (33/37) 93.8% (15/16) 91.3% (94/103)
95% CI (80.8–97.8) (74.6–97.0) (69.8–99.8) (84.1–95.9)
Day 28 (PCR corrected) 96.0% (48/50) 94.6% (35/37) 93.8% (15/16) 95.1% (98/103)
95% CI (86.3–99.5) (81.8–99.3) (69.8–99.8) (89.0–98.4)
Cure rate PP %(n/M)1 (uncorrected) N = 45 N = 34 N = 14 N = 93
Day 7 100% (45/45) 100% (34/34) 100% (14/14) 100% (93/93)
Day 14 100% (45/45) 100% (34/34) 100% (13/13) 100% (92/92)
Day 28 95.6% (43/45) 94.1% (32/34) 100% (13/13) 95.7% (88/92)
95% CI (84.9–99.5) (80.3 – 99.3) (-) (89.2 – 98.8)
PCT (h) ITT N = 50 N = 37 N = 16 N = 103
Mean ± SE 24.8 ± 1.3 26.2 ± 2.31 21.2 ± 4.33 24.9 ± 1.28
Range 5.3 – 47.8 7.7 – 59.9 7.2 – 71.1 5.3–71.1
Median 23.8 23.8 23.0 23.8
95%CI2 (23.7–23.9) (23.1–35.3) (7.9–23.8) (23.7–23.8)
FCT (h) ITT) N = 50 N = 37 N = 16 N = 103
Mean ± SE 24.5 ± 3.81 17.6 ± 2.04 44.2 ± 19.98 26.1 ± 4.14
Range 3.5 – 163.8 4.1 – 47.5 7.2–308.7 3.5–308.7
Median 23.4 8.2 15.4 22.4
(95% CI)2 (7.8–23.8) (7.8–23.4) (7.8–34.6) (7.9–23.5)
1In some instances N is different from M as M = number of patients who had the measurement at given time point
2The CI is provided for the medianMalaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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Serious adverse events
One serious adverse event was recorded during the study.
A child in BWG2 died at home on day 9 of the study
within a few hours of onset of severe gastroenteritis with-
out having been seen by the study team or by any medical
personnel. This serious adverse event was not considered
drug-related. The study team received information of the
death a day after the event when two other siblings (who
were not enrolled in the study) developed similar illnesses
and were brought to the study team for treatment. The sib-
lings were diagnosed as having cholera. They responded
well to treatment and went home well recovered. A verbal
autopsy was conducted to identify the cause of death of
the study participant.
Electrocardiographic parameters
No patient reported any symptomatic cardiac adverse
event. Mean heart rate and RR intervals at enrollment were
140.8 ± 21.41/min and 437.0 ± 70.15 ms while day 3 fig-
ures were 119.8 ± 21.36/min and 518.4 ± 100.8 ms
respectively. There was a slight increase in mean PR and
QTc intervals between day 0 and day 3. The mean PR
interval increased from 117.7 ± 14.84 ms at enrollment to
126.9 ± 19.52 ms on day 3. The mean QTc values on days
0 and 3 were 400.6 ± 23.64 ms and 410 ± 21.31 ms respec-
tively. There was no record of a QTc interval greater than
500 ms using Bazett's formula. However 6 patients (3, 2,
& 1 in BWG1, BWG2 and BWG3 respectively) recorded
QTc interval prolongation of over 60 ms on day 3 when
compared with day 0. All were asymptomatic.
Discussion
This report presents the details of data obtained in the
Nigerian arm of the multicentre study evaluating the
safety and efficacy of AL in Kenya, Tanzania and Nigeria
[12]. The six-dose regimen of AL was found to be well tol-
erated, safe and highly efficacious in the treatment of
acute uncomplicated P. falciparum malaria in Nigerian
children and infants weighing as little as 5 kg. The young-
est child in this study was five weeks of age. Three of the
enrollees were less than six months of age while 48.5%
were less than two years of age (Table 2).
The main thrust of the multicentre study reported by
Falade et al [12], is the safety of the six-dose regimen of AL.
This paper presents a more detailed report of the findings
among Nigerian children with a view to providing addi-
tional information to practitioners in Nigeria who are
often anxious about the choice of anti-malarial drugs out-
side chloroquine and sulphadoxine-pyrimethamine when
treating very young infants. The good safety profile
obtained among Nigerian children treated with AL is com-
parable with findings during pre-registration studies of
the four-dose regimen in Nigeria [14-17]. There were no
reports of drug-related serious adverse events. In the mul-
ticentre study [12], only one (urticaria) of six serious
adverse events was considered drug-related. Other
recorded adverse events during the study were generally
mild. Adverse events such as anaemia, cough, diarrhoea
and vomiting (Tables 4 and 5) are difficult to distinguish
from the clinical features of the disease (malaria) being
treated. Tolerability of the drug was also quite good and
no patient was withdrawn because of recurrent vomiting.
There were 17 episodes of rash among the Nigerian chil-
dren enrolled in the study. The rashes were sometimes
pruritic, but were all transient clearing spontaneously
within three days without any specific therapy. Some (7)
of the rashes were classified as possibly drug-related.
Table 4: Adverse events after baseline but before recurrence of parasitaemia occurring in > 5% of patients, by body weight group
Adverse Events n (%)
BWG1
5-<10 kg
(N = 50)
BWG2
10-<15 kg
(N = 37)
BWG3
15-<25 kg
(N = 16)
Ttotal
5-<25 kg
(N = 103)
Anaemia 32 (64.0) 20 (54.1) 7 (43.8) 59 (57.3)
Cough 20 (40.0) 11 (29.7) 2 (12.5) 33 (32.0)
Hepatomegaly 9 (18.0) 12 (32.4) 5 (31.3) 26 (25.2)
Respiratory tract infection 21 (42.0) 9 (24.3) 1 (6.3) 31 (30.1)
Splenomegaly 10 (20.0) 9 (24.3) 2 (12.5) 21 (20.4)
Diarrhoea 11 (22.0) 7 (18.9) 2 (12.5) 20 (19.4)
Vomiting 10 (20.0) 3 (8.1) 5 (31.3) 18 (17.5)
Rashes 11 (22.0) 5 (13.5) 1 (6.3) 17 (16.5)
Anorexia 9 (18.0) 5 (13.5) 1 (6.3) 15 (14.6)
Clonus 7 (14.0) 5 (13.5) 1 (6.3) 13 (12.6)
Insomnia 7 (14.0) 3 (8.1) 1 (6.3) 11 (10.7)
Catarrh 4 (8.0) 5 (13.5) 0 (0.0) 9 (8.7)
Hypothermia 5 (10.0) 1 (2.7) 0 (0.0) 6 (5.8)
Hyperreflexia 3 (6.0) 2 (5.4) 1 (6.3) 6 (5.8)Malaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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Lefèvre et al [7] had earlier reported similar episodes of
pruritic rash in a study in Thailand. Hypothermia was
recorded in six children (5 BWG1, 1 BWG2) during rou-
tine six-hourly temperature recording – a routine ward
practice in the hospital where the study was conducted.
There was no mention of hypothermia in the larger study
report by Falade et al [12] as only adverse events which
occurred in > 2% of the total study population were listed.
The significance of the hypothermia is uncertain, as over
40% of children in BWG1 were less than 12 months of age
(Table 2). The delicate body temperature regulation in
this age group is well recognized.
Earlier reports of neurological abnormalities in some
experimental animals notably dogs and Sprague-Dawley
rats [9,10] during toxicological studies have been a major
concern in the therapeutic use of artemisinin derivatives.
Special attention was paid to neurological TESS evalua-
tion pre-enrollment and at days 3, 7, 14 and 28 evalua-
tions. It is noteworthy that no significant neurological
abnormalities were recorded during this study. Transient
ankle clonus, hyperreflexia and insomnia were the only
neurological abnormalities observed among the children
enrolled in Nigeria. These observations were made during
the treatment phase of the study. Anxiety induced by hos-
pitalisation and associated ward routines (twice daily
TESS and blood film preparation, drug administration
etc) could explain some of these observed neurological
adverse events. The lack of electrocardiographic evidence
of cardiotoxicity and specifically on the QTc evaluation
during this study is consistent with previous findings in
both healthy volunteers and in patients suffering from
acute uncomplicated malaria who received AL and con-
firms previous findings that lumefantrine lacks the cardi-
otoxicity of halofantrine [18,19].
The PCR corrected cure rates on days 7, 14 and 28 were
100% in all body weight groups. Additional efficacy indi-
cators were rapid fever clearance and parasite clearance
(Table 3). Other clinical features associated with malaria
apart from fever also cleared rapidly. These results are con-
sistent with previous studies [7,14,20]. Abdu-Aguye et al
[14] in a pre- registration study of the four-dose regimen
in Zaria, Northern Nigeria recorded a 100% cure rate at
day 14 among 50 patients aged two to 65 years suffering
from acute uncomplicated malaria. On the other hand,
the efficacy results recorded in this report are superior to
those obtained from some earlier studies with the four-
dose regimen in Nigeria. Salako et al [17] reported cure
rates of 87% and 73% on days 7 and 14 respectively
among children aged two to 12 years, Ezedinachi et al [16]
reported 96% and 93% cure rates on days 7 and 14 from
Calabar, Nigeria. Also working in Nigeria, Eke et al [15]
recorded a day 7 cure rate of 88% among 57 patients aged
two to 16 years in Port Harcourt.
The superior efficacy of the six-dose regimen used in this
study when compared with that of the four-dose regimen
is consistent with findings in similar studies that evalu-
ated the four-dose and six-dose regimens in the western
border of Thailand, in Tanzania, Kenya and the Gambia
[7,12,21]. Meremikwu et al [22] working in Calabar,
Nigeria recorded a day 14 uncorrected PCR cure rate of
87% among the 54 children they studied (evaluable pop-
ulation). Two of the children in their study had late clini-
cal failure, while five had late parasitological failure. The
PCR uncorrected day 14 cure rate in the study being
reported was 100% among the PP population. However,
Meremikwu et al [22] did not report the PCR corrected
cure rate, and so could not differentiate between re-infec-
tion and recurrence. A day 14 uncorrected cure rate of
87% is not unexpected in a high transmission geographi-
cal region where re-infection is frequent. In addition,
there are other factors that could account for this such as
a smaller per protocol population of 54 compared to 93
patients in the present study. The patients in this study
Table 5: Adverse events (occurring after baseline but before recurrence of parasitaemia in > 2% of children) suspected by investigators 
to be related to study medication by body weight group
Adverse Events n (%)
BWG1
5-<10 kg
(N = 50)
BWG2
10-<15 kg
(N = 37)
BWG3
15-<25 kg
(N = 16)
Total
5-<25 kg
(N = 103)
At least one adverse event 30 (60.0) 16 (43.2) 6 (37.5) 52 (50.5)
Anaemia 7 (14.0) 6 (16.2) 1 (6.3) 14 (13.6)
Diarrhoea 5 (10.0) 5 (13.5) 1 (6.3) 11 (10.7)
Clonus 7 (14.0) 5 (13.5) 1 (6.3) 13 (12.6)
Vomiting 7 (14.0) 0 (-) 4 (25.0) 11 (10.7)
Rashes 4 (8.0) 3 (8.1) 0 (-) 7 (6.8)
Hyperreflexia 1 (2.0) 2 (5.4) 1 (6.3) 4 (3.9)
Cough 2 (4.0) 1 (2.7) 0 (-) 3 (2.9)Malaria Journal 2008, 7:246 http://www.malariajournal.com/content/7/1/246
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were admitted during the treatment phase of the study
thus ensuring 100% supervised dosing. In addition, AL
was administered with a fatty meal: sweetened condensed
milk for older children while infants were breast-fed soon
after dosing during this study. This was done to enhance
the bioavailability of lumefantrine. Ashley et al [23], in a
recent pharmacokinetic study of healthy volunteers,
reported a dose response relationship between the vol-
ume of soya milk administered and lumefantrine bioa-
vailability. Furthermore the study reported by Ashley et al
showed that administration of AL with soya milk at a
quantity which corresponds to 1.2 g of fat increased lume-
fantrine area under the curve (AUC) by more than five
fold. This underscores the importance of educating health
care workers, patients and caregivers of the importance of
compliance and the need to administer AL with food that
contains fat, be it conventional milk, soya milk or some
appropriate local food.
Artemisinin containing anti-malarial combinations is
known to induce rapid parasite clearance and high parasi-
tological cure rates. This expectation was met by the
response profile obtained in this study. Approximately
75% of the PP population was free of patent parasitaemia
24 hours after initiation of therapy while none of the
study population had detectable peripheral parasitaemia
by day 3.
Conclusion
In conclusion, the six-dose regimen of AL is safe and effec-
tive in the management of acute uncomplicated falci-
parum malaria in Nigerian infants and children weighing
as little as five kg, including non-immune children in an
area of worsening drug resistant falciparum malaria. The
results of this study suggest that if properly deployed, AL
could lead to a reduction and may also contribute to a sig-
nificant extent in halting the worsening morbidity and
mortality from malaria on the African continent [1,2]. The
Federal government of Nigeria recently changed its
malaria treatment policy from chloroquine to artemisi-
nin-based combination therapy as a first line drug with a
preference for AL and artesunate plus amodiaquine in that
order [24]. It is important to design appropriate informa-
tion, education and communication materials, which will
educate patients, parents, guardians and health care work-
ers alike on correct treatment regimen and the need to
administer AL with food and that will encourage compli-
ance as part of the efforts at prolonging the useful thera-
peutic life of this combination.
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